Author:
Drs. Kira Smith MD, MSc in Experimental Medicine and Forensic Pathology
E-mail: girlboss@vendettacartel.com
Phone: +39 351 248 9284
Date: Apr. 07, 2024
Abstract:
Now that mRNA vaccines have ended their sense phase, in preparation for which they were created and placed on the world market, now seemingly dissolved with the disappearance of a high incidence in infections and deaths due to Sars-CoV-2 virus, another research challenge arises: degrading the mRNA in those who received the inoculation, as they will surely have developed antibodies and immune response by now to be able to fight off any future exposure to the pathogen, but especially in regard to recent studies substantiating the possibility of detecting mRNA fragments or Spike protein within the body up to 6 months after the last vaccination, in addition to the various manifestations similar to those that have arisen as symptoms of Sars-CoV-2 disease, part of the syndrome referred to as Long-Covid, although nonspecific and of varying severity, has in some cases been the occurrence of clinically remarkable events. A Ribonuclease enzyme, called Ranpirnase, associated with a monoclonal antibody at the beginning of its introduction as a therapeutic option for a variety of purposes, derive from the ICSM18 mouse anti-PrPC antibody, called PRN100, was considered for this. The two elements, when combined, would form an engineered compound called Immunornase, capable of preventing the appearance of effects due to the production of unanticipated proteins by preventing their production and, at the same time, counteracting any iatrogenically symptomatic activity.
DOI: 10.13140/RG.2.2.33853.47841
The article is submitted to SSRN, Authorea, Medrxiv and F1000 Research, in addition to awaiting for sending the paper to the international trade leading journals, such as: PLOS, JAMA, Nature, MDPI, SAGE, Wiley and more.